Helicobacter pylori eradication therapy may facilitate gastric ulcer healing after endoscopic mucosal resection: A prospective randomized study

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Background and Aim: It remains unclear whether Helicobacter pylori eradication therapy affects the healing rate of iatrogenic ulcers following endoscopic mucosal resection (EMR) for gastric tumors. The aim of our study was to prospectively evaluate the effect of H. pylori eradication therapy on gastric ulcer healing after EMR. Methods: After EMR, patients were randomly assigned to either the H. pylori eradication group (Hp group) (lansoprazole 30 mg, amoxicillin 1000 mg, and clarithromycin 500 mg, twice a day for 7 days) or the noneradication group (proton pump inhibitor, PPI group) (lansoprazole 30 mg, twice a day for 7 days). Four weeks after EMR, the ulcer stages and size were compared between the two groups. Moreover, ulcer-related symptoms, bleeding rates, adverse effects, and drug compliance were compared. Results: A total of 64 patients were enrolled. Of these, 17 patients were excluded from the study. The two groups were comparable in terms of baseline clinicopathologic characteristics. Four weeks after EMR, the two groups did not differ with respect to ulcer stage (p =.475) or ulcer-related symptoms (p =.399). However, the ulcer reduction ratio was significantly higher in the Hp group (0.028 ± 0.024 vs. 0.065 ± 0.055, p <.05). No differences were observed between the two groups with regard to drug compliance, adverse drug event rates, or bleeding rates. Conclusions: Our results suggest that H. pylori eradication therapy might improve the ulcer healing rate after EMR.

Original languageEnglish
Pages (from-to)564-571
Number of pages8
JournalHelicobacter
Volume13
Issue number6
DOIs
Publication statusPublished - 2008 Dec 1

Fingerprint

Stomach Ulcer
Helicobacter pylori
Ulcer
Prospective Studies
Lansoprazole
Therapeutics
Hemorrhage
Clarithromycin
Proton Pump Inhibitors
Amoxicillin
Endoscopic Mucosal Resection
Drug-Related Side Effects and Adverse Reactions
Pharmaceutical Preparations
Stomach
Neoplasms

All Science Journal Classification (ASJC) codes

  • Gastroenterology
  • Infectious Diseases

Cite this

@article{d2f97b3ef5ea4541b841362690baf0dc,
title = "Helicobacter pylori eradication therapy may facilitate gastric ulcer healing after endoscopic mucosal resection: A prospective randomized study",
abstract = "Background and Aim: It remains unclear whether Helicobacter pylori eradication therapy affects the healing rate of iatrogenic ulcers following endoscopic mucosal resection (EMR) for gastric tumors. The aim of our study was to prospectively evaluate the effect of H. pylori eradication therapy on gastric ulcer healing after EMR. Methods: After EMR, patients were randomly assigned to either the H. pylori eradication group (Hp group) (lansoprazole 30 mg, amoxicillin 1000 mg, and clarithromycin 500 mg, twice a day for 7 days) or the noneradication group (proton pump inhibitor, PPI group) (lansoprazole 30 mg, twice a day for 7 days). Four weeks after EMR, the ulcer stages and size were compared between the two groups. Moreover, ulcer-related symptoms, bleeding rates, adverse effects, and drug compliance were compared. Results: A total of 64 patients were enrolled. Of these, 17 patients were excluded from the study. The two groups were comparable in terms of baseline clinicopathologic characteristics. Four weeks after EMR, the two groups did not differ with respect to ulcer stage (p =.475) or ulcer-related symptoms (p =.399). However, the ulcer reduction ratio was significantly higher in the Hp group (0.028 ± 0.024 vs. 0.065 ± 0.055, p <.05). No differences were observed between the two groups with regard to drug compliance, adverse drug event rates, or bleeding rates. Conclusions: Our results suggest that H. pylori eradication therapy might improve the ulcer healing rate after EMR.",
author = "JaeHee Cheon and Jie-Hyun Kim and SangKil Lee and Kim, {Tae Il} and Kim, {Won Ho} and Yongchan Lee",
year = "2008",
month = "12",
day = "1",
doi = "10.1111/j.1523-5378.2008.00647.x",
language = "English",
volume = "13",
pages = "564--571",
journal = "Helicobacter",
issn = "1083-4389",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Helicobacter pylori eradication therapy may facilitate gastric ulcer healing after endoscopic mucosal resection

T2 - A prospective randomized study

AU - Cheon, JaeHee

AU - Kim, Jie-Hyun

AU - Lee, SangKil

AU - Kim, Tae Il

AU - Kim, Won Ho

AU - Lee, Yongchan

PY - 2008/12/1

Y1 - 2008/12/1

N2 - Background and Aim: It remains unclear whether Helicobacter pylori eradication therapy affects the healing rate of iatrogenic ulcers following endoscopic mucosal resection (EMR) for gastric tumors. The aim of our study was to prospectively evaluate the effect of H. pylori eradication therapy on gastric ulcer healing after EMR. Methods: After EMR, patients were randomly assigned to either the H. pylori eradication group (Hp group) (lansoprazole 30 mg, amoxicillin 1000 mg, and clarithromycin 500 mg, twice a day for 7 days) or the noneradication group (proton pump inhibitor, PPI group) (lansoprazole 30 mg, twice a day for 7 days). Four weeks after EMR, the ulcer stages and size were compared between the two groups. Moreover, ulcer-related symptoms, bleeding rates, adverse effects, and drug compliance were compared. Results: A total of 64 patients were enrolled. Of these, 17 patients were excluded from the study. The two groups were comparable in terms of baseline clinicopathologic characteristics. Four weeks after EMR, the two groups did not differ with respect to ulcer stage (p =.475) or ulcer-related symptoms (p =.399). However, the ulcer reduction ratio was significantly higher in the Hp group (0.028 ± 0.024 vs. 0.065 ± 0.055, p <.05). No differences were observed between the two groups with regard to drug compliance, adverse drug event rates, or bleeding rates. Conclusions: Our results suggest that H. pylori eradication therapy might improve the ulcer healing rate after EMR.

AB - Background and Aim: It remains unclear whether Helicobacter pylori eradication therapy affects the healing rate of iatrogenic ulcers following endoscopic mucosal resection (EMR) for gastric tumors. The aim of our study was to prospectively evaluate the effect of H. pylori eradication therapy on gastric ulcer healing after EMR. Methods: After EMR, patients were randomly assigned to either the H. pylori eradication group (Hp group) (lansoprazole 30 mg, amoxicillin 1000 mg, and clarithromycin 500 mg, twice a day for 7 days) or the noneradication group (proton pump inhibitor, PPI group) (lansoprazole 30 mg, twice a day for 7 days). Four weeks after EMR, the ulcer stages and size were compared between the two groups. Moreover, ulcer-related symptoms, bleeding rates, adverse effects, and drug compliance were compared. Results: A total of 64 patients were enrolled. Of these, 17 patients were excluded from the study. The two groups were comparable in terms of baseline clinicopathologic characteristics. Four weeks after EMR, the two groups did not differ with respect to ulcer stage (p =.475) or ulcer-related symptoms (p =.399). However, the ulcer reduction ratio was significantly higher in the Hp group (0.028 ± 0.024 vs. 0.065 ± 0.055, p <.05). No differences were observed between the two groups with regard to drug compliance, adverse drug event rates, or bleeding rates. Conclusions: Our results suggest that H. pylori eradication therapy might improve the ulcer healing rate after EMR.

UR - http://www.scopus.com/inward/record.url?scp=55949108136&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55949108136&partnerID=8YFLogxK

U2 - 10.1111/j.1523-5378.2008.00647.x

DO - 10.1111/j.1523-5378.2008.00647.x

M3 - Article

C2 - 19166423

AN - SCOPUS:55949108136

VL - 13

SP - 564

EP - 571

JO - Helicobacter

JF - Helicobacter

SN - 1083-4389

IS - 6

ER -